Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

Patent metadata

Field	Value
Publication number	US-11141393-B2
Application number	US-201816137629-A
Country	US
Kind code	B2
Filing date	Sep 21, 2018
Priority date	Jan 9, 2013
Publication date	Oct 12, 2021
Grant date	Oct 12, 2021

Abstract

Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

First claim

The invention claimed is:

1. A method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a composition comprising (i) a part of a culture medium that has been in contact with a mesenchymal stem cell (MSC) and contains one or more components of the MSC, wherein the component(s) of the MSC comprises a microRNA, a messenger RNA, a non-coding RNA, a mitochondria, a growth factor, or combinations thereof, or (ii) an exosome derived from the MSC, wherein the vasculopathy is selected from the group consisting of pulmonary arterial hypertension (PAH), peripheral vascular disease (PVD), critical limb ischemia (CLI), coronary artery disease and diabetic vasculopathy.

2. The method of claim 1 , wherein the prostacyclin and the composition are administered concurrently.

3. The method of claim 1 , wherein the prostacyclin and the composition are administered separately.

4. The method of claim 1 , further comprising, prior to the administration, contacting the part of the culture medium with a prostacyclin.

5. The method of claim 1 , wherein the component(s) of the MSC is selected from the group consisting of an exosome, a microvesicle, a microRNA, a messenger RNA, a non-coding RNA, a mitochondria, a growth factor, and combinations thereof.

6. The method of claim 1 , wherein the prostacyclin is selected from the group consisting of epoprostenol, treprostinil, beraprost, ilprost, a PGI 2 receptor agonist, and pharmaceutically acceptable salts thereof.

7. The method of claim 6 , wherein the prostacyclin is treprostinil or a pharmaceutically acceptable salt or ester thereof.

8. The method of claim 1 , wherein the MSC is a mesenchymal precursor cell (MPC).

9. The method of claim 1 , wherein the MSC is obtained from bone marrow.

10. The method of claim 1 , wherein an exosome derived from the MSC is administered to the subject.

Assignees

• United Therapeutics Corp

Inventors

• Jeffs Roger
• Petersen Thomas
• Ilagan Roger M
• Wade Michael

Classifications

• A61K31/5585 Primary

  having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin · CPC title

• A61P9/14

  Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• C12N2501/02

  Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes · CPC title